Fenspiride

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Fenspiride
Fenspiride.svg
Fenspiride ball-and-stick model.png
Clinical data
Trade namesEurespal, Pneumorel
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability90%[1]
Elimination half-life14–16 hours
ExcretionUrine (90%), feces (~10%)
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.023.411 Edit this at Wikidata
Chemical and physical data
FormulaC15H20N2O2
Molar mass260.331 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Fenspiride (INN, brand names Eurespal, Pneumorel and others) is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases.[2] The pharmacotherapeutic classification is antitussives. In Russia it was approved for the treatment of acute and chronic inflammatory diseases of ENT organs (ear, nose, throat) and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis), as well as for maintenance treatment of asthma.[3]. Russia, Romania, France and other European countries withdrew fenspiride-based drugs from the market due to the risk of QT prolongation and torsades de pointes.[4]

References[edit]

  1. ^ Montes, B; Catalan, M; Roces, A; Jeanniot, JP; Honorato, JM (1993). "Single dose pharmacokinetics of fenspiride hydrochloride: phase I clinical trial". European Journal of Clinical Pharmacology. 45 (2): 169–72. doi:10.1007/bf00315501. PMID 7901024.
  2. ^ Płusa T, Nawacka D (Dec 1998). "Efficacy and tolerance of fenspiride in adult patients with acute respiratory tract infections". Pol Merkur Lekarski. 5 (30): 368–71. PMID 10101527.
  3. ^ "Эреспал® (Eurespal®) Prescribing Information. VIDAL Drug Compendium" (in Russian). Retrieved 6 February 2014.
  4. ^ "Fenspiride containing medicinal products". European Medicines Agency. 2019-02-15. Retrieved 2019-06-12.